



FOR IMMEDIATE RELEASE

**Selexis SA Enters Cooperative Agreement with Cambrex Corporation
To Use Selexis' SURE Technology Platform for Mammalian Cell Line Development**

Geneva, Switzerland – May 23, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins, announced today that it has entered into cooperative agreements with two Cambrex Corporation (“Cambrex”) subsidiaries, Cambrex Bio Science Baltimore, Inc. and Cambrex Bio Science Walkersville, Inc.. Under the agreement, Cambrex will have access to Selexis' SURE engineered cell lines and expertise. Additionally, Selexis will utilize Cambrex's expertise to produce data that will help maintain high productivity of the Selexis cell lines in Cambrex's PowerCHO™ media.

Specifically, Cambrex will use Selexis' SURE engineered cell lines in Cambrex bioreactors to commercially produce recombinant therapeutic proteins. Concurrently, Cambrex will capture data that will help identify specific bioreactor processes and media that may maintain high productivity of the Selexis SURE cell lines.

“This is a ‘win-win’ agreement that provides significant benefits to both Selexis and Cambrex,” said Dr. Igor Fisch, CEO, Selexis SA. “Our SURE Cell Line DevelopmentSM will help Cambrex grow their protein and antibody production business, and the data that Cambrex scientists generate will be a tremendous help to us in validating the high productivity rates of the SURE cell lines on a commercial scale.”

Selexis' SURE Technology Platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in ten weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.

- more -

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655, Montgomery St. STE 540
94111 San Francisco
USA

T +1 415 273 51 41
F +1 415 837 32 04

“We have been actively searching for technologies to enhance our protein and antibody production business,” said Peter van Hoorn, Executive Vice President, Business Development, Cambrex Biopharma. “After thoroughly investigating options, we are confident that cell lines engineered with Selexis’ SURE technology, in combination with our PowerCHO media, can offer customers outstanding results. By using Selexis’ SURE cell line platform, we have removed the need to license several expression and cell line technologies, which means our customers are less encumbered by royalty payments.”

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services. Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing. The Company’s unique SURE Technology Platform, which includes Selexis’ fourth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

About Cambrex

Cambrex Corporation is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 2000 worldwide. For more information, please visit <http://www.cambrex.com>.

PowerCho™ is a trademark of Cambrex Corporation or its subsidiaries.

Selexis SA Enters Cooperative Agreement with Cambrex Corporation

Page 3

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

CAMBREX CONTACT:

Biopharma Sales
877.676.5888
biopharmainfo@cambrex.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
igor.fisch@selexis.com

UNITED STATES
Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com

#